-
公开(公告)号：US10690674B2
公开(公告)日：2020-06-23
申请号：US15578874
申请日：2016-06-02
发明人： Xi-Tao Wang , Olufemi A. Adelakun , Anne C. Lewin , Alan J. Korman , Mark J. Selby , Changyu Wang , Haichun Huang , Karla A. Henning , Nils Lonberg , Mohan Srinivasan , Michelle Minhua Han , Guodong Chen , Richard Y. Huang , Indrani Chakraborty , Susan Chien-Szu Wong , Huiming Li
IPC分类号： G01N33/566 , G01N33/574 , C07K16/28
摘要： Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
公开(公告)号：US10683357B2
公开(公告)日：2020-06-16
申请号：US15474731
申请日：2017-03-30
发明人： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC分类号： C07H21/04 , C12P21/06 , C12N15/87 , C12N1/20 , C12N5/20 , C12N15/00 , C07K16/28 , C07K16/30 , A61P35/00 , A61K39/395 , G01N33/574 , A61K39/00
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US10316091B2
公开(公告)日：2019-06-11
申请号：US16024333
申请日：2018-06-29
发明人： John P. Cogswell , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574 , A61K39/00
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US20190135920A1
公开(公告)日：2019-05-09
申请号：US16248222
申请日：2019-01-15
发明人： John P. Cogswell , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574
CPC分类号： C07K16/2818 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/76 , G01N33/57492 , G01N2333/70596 , G01N2800/52 , Y02A50/41 , Y02A50/412
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US10266595B2
公开(公告)日：2019-04-23
申请号：US16213960
申请日：2018-12-07
发明人： John P. Cogswell , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574 , A61K39/00
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US20240002512A1
公开(公告)日：2024-01-04
申请号：US18052076
申请日：2022-11-02
发明人： John P. COGSWELL , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574
CPC分类号： C07K16/2818 , C07K16/2827 , A61K39/3955 , C07K16/18 , C07K16/2803 , G01N33/57492 , A61K2039/505
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US10604575B2
公开(公告)日：2020-03-31
申请号：US16231211
申请日：2018-12-21
发明人： John P. Cogswell , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574 , A61K39/00
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US10577423B2
公开(公告)日：2020-03-03
申请号：US16248222
申请日：2019-01-15
发明人： John P. Cogswell , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574 , A61K39/00
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US10266596B1
公开(公告)日：2019-04-23
申请号：US16213965
申请日：2018-12-07
发明人： John P. Cogswell , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , G01N33/574 , C07K16/18 , A61K39/00
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
公开(公告)号：US20190112376A1
公开(公告)日：2019-04-18
申请号：US16230657
申请日：2018-12-21
发明人： John P. COGSWELL , Stacie M. Goldberg , Ashok K. Gupta , Maria Jure-Kunkel , Xi-Tao Wang , Jon M. Wigginton
IPC分类号： C07K16/28 , A61K39/395 , C07K16/18 , G01N33/574
摘要： The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.038 秒)
